JOUNCE THERAPEUTICS
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.
JOUNCE THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.jouncetx.com
Total Employee:
101+
Status:
Active
Contact:
617-585-2000
Total Funding:
194.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag
Similar Organizations
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Rani Therapeutics
Rani Therapeutics develops bio-therapeutics technology for the oral delivery of large drug molecules.
Resolve Therapeutics
Resolve Therapeutics is focused on developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE).
Rodeo Therapeutics
Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.
Resonant Therapeutics
Resonant Therapeutics is a scalable tumor microenvironment platform that speeds up therapeutic & goal discovery.
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
Nivien Therapeutics
Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Nimble Therapeutics
Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.
Veralox Therapeutics
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Verseon
Verseon’s breakthroughs in computational chemistry, AI, & synthesis create novel pharmaceuticals. Atom by atom, we drive innovation.
Verseau Therapeutics
Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.
Ventus Therapeutics
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
VasoRx
VasoRx is developing RNA therapies for diseases of the cardiovascular system & oncology such as atherosclerosis and pulmonary hypertension.
Memgen
Memgen is a clinical stage biotech developing cancer immunotherapies to harness the power of the immune system to cure cancer
Modus Therapeutics
Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.
MyoScience
MyoScience develops and commercializes technology-driven dermatological products.
Lassen Therapeutics
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
Aqualung Therapeutics
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Actuate Therapeutics
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aligos Therapeutics
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Alcyone Therapeutics
Alcyone Therapeutics is Pioneering Next-Generation Precision CNS Genetic Therapies to unlock new possibilities
APIM Therapeutics
APIM Therapeutics is developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen).
Adagio Therapeutics
Adagio Therapeutics offers research and development of therapeutic pharmaceuticals related to COVID-19.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Allena Pharmaceuticals
Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.
Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Altor BioScience
Altor BioScience researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
BeneVir Biopharm
Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.
Bioject Medical Technologies
Bioject Medical Technologies develops needle-free injection therapies to improve the administration of liquid medications such as vaccines.
Faraday Pharmaceuticals
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
7 Hills Pharma
7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.
TxCell
TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.
TYME
TYME is an emerging biotech developing cancer therapeutics intended to be broadly effective across tumor types with low toxicity profiles.
Tau Therapeutics
Tau Therapeutics engages in the R&D, repositioning and commercialization of calcium T-channel therapies for oncology and other diseases.
Taiga Biotechnologies
Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer.
Janux Therapeutics
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Annovis Bio
Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Kineta
Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Kodikaz Therapeutic Solutions
Kodikaz is a gene therapy platform company that has the unique technical ability of specifically targeting cancer cells.
Walking Fish Therapeutics
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system.
Wugen
Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Sequoia Sciences
Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers.
SyntheX
SyntheX is a biotechnology company reimagining precision therapeutics with new drug discovery technologies focused on protein modulation.
Dignify Therapeutics
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal.
HDT Bio
IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.
Heptares Therapeutics
Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Immune Pharmaceuticals
Immune Pharmaceuticals applies a personalized approach to treatment and developing novel antibody therapeutics.
Iconic Therapeutics
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.
IRX Therapeutics
IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases.
Imcyse
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
INmuneBIO
INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.
GenEdit
GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.
GITR
GITR develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.
GO Therapeutics
A new generation of cancer immunotherapy promise to change the paradigm of cancer treatment.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
G-CON Manufacturing
G-CON Manufacturing designs, produces, and installs prefabricated cleanrooms called PODs.
Coferon
Coferon employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells.
CytunePharma
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.
Carmine Therapeutics
Carmine Therapeutics is developing novel types of gene therapies that utilize extracellular vesicles (EVs) produced in the laboratory.
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Cybrexa Therapeutics
Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.
Cour Pharmaceuticals Development
Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Prelude Therapeutics
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Pear Therapeutics
Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Porton Advanced Solutions
Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.
PRISM BioLab
PRISM develop therapeutic drugs that cure these intractable diseases using our unique peptide mimic technology.
ProTom International
ProTom International is a leading device manufacturer of proton therapy technology.
Pulmatrix
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.
Current Advisors List
Board_member
2017-10-23
Board_member
2016-06-01
Board_member
2013-01-01
Board_member
Board_member
2015-11-01
Board_member
2021-09-01
Current Employees Featured
Padmanee Sharma Founder @ Jounce Therapeutics
Founder
Julia Keith Business Development Manager @ Jounce Therapeutics
Business Development Manager
2019-03-01
Cary Pfeffer Interim CEO @ Jounce Therapeutics
Interim CEO
Thomas F. Gajewski Founder @ Jounce Therapeutics
Founder
Kim Drapkin CFO @ Jounce Therapeutics
CFO
2015-08-01
Allison Nance Senior Vice President, Regulatory Affairs & Quality Assurance @ Jounce Therapeutics
Senior Vice President, Regulatory Affairs & Quality Assurance
2016-05-01
Drew Pardoll Founder @ Jounce Therapeutics
Founder
Stephen Farrand Chief Technical Officer @ Jounce Therapeutics
Chief Technical Officer
2016-09-01
Robert Kamen Interim Chief Technology Officer @ Jounce Therapeutics
Interim Chief Technology Officer
2013-01-01
Hugh M Cole Chief Business Officer & Head of Corporate Development @ Jounce Therapeutics
Chief Business Officer & Head of Corporate Development
2017-08-01
Founder
Stock Details
Investors List
Casdin Capital
Casdin Capital investment in Series B - Jounce Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Jounce Therapeutics
Omega Funds
Omega Funds investment in Series B - Jounce Therapeutics
Wellington Management
Wellington Management investment in Series B - Jounce Therapeutics
Nextech Invest
Nextech Invest investment in Series B - Jounce Therapeutics
Redmile Group
Redmile Group investment in Series B - Jounce Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Jounce Therapeutics
Inbio Ventures
Inbio Ventures investment in Series B - Jounce Therapeutics
Pharmstandard
Pharmstandard investment in Series B - Jounce Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series A - Jounce Therapeutics
Official Site Inspections
http://www.jouncetx.com Semrush global rank: 3.34 M Semrush visits lastest month: 4.78 K
- Host name: 104.21.62.152
- IP address: 104.21.62.152
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Jounce Therapeutics"
Jounce Therapeutics - Crunchbase Company Profile
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous …See details»
Jounce Therapeutics Enters Into Agreement to Be Acquired by …
Mar 27, 2023 Pursuant and subject to the terms of the merger agreement, a subsidiary of Concentra will commence a tender offer by April 7, 2023 to acquire all outstanding shares of …See details»
Redx and Jounce Announce Recommended Business Combination …
Feb 23, 2023 Management and Organization. Named Redx Inc., the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX. Led by current Redx CEO …See details»
Jounce Therapeutics, Inc. Information - RocketReach
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack …See details»
Jounce Therapeutics, Inc. | LinkedIn
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and ...See details»
Redx and Jounce Announce Recommended Business Combination
Mar 3, 2023 The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value …See details»
Redx and Jounce Announce Recommended Business Combination
Feb 23, 2023 Management and Organization Named Redx Inc. , the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX. Led by current Redx CEO …See details»
Jounce Therapeutics Announces Closing of Tender Offer - Yahoo …
May 4, 2023 The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023. As of the expiration of the offer, 36,367,727 shares of Jounce common stock had been validly tendered …See details»
Jounce Therapeutics - Craft
May 5, 2023 Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies …See details»
Gilead Sciences and Jounce Therapeutics Announce Exclusive …
Sep 1, 2020 Jounce expects JTX-8064 to enter the clinic in 2020. JTX-1811 is a monoclonal antibody targeting CCR8 which is designed to selectively deplete T regulatory cells in the …See details»
Jounce Therapeutics Enters Into Agreement to Be Acquired by
Mar 27, 2023 Jounce Therapeutics, Inc. Kim Drapkin ir@jouncetx.com: T: +1-857-259-3840 Cowen (Financial Adviser to Jounce) T: +1-646-562-1010: Tanya Joseph / Erik Schuchard / …See details»
Jounce Therapeutics Appoints Jigar Raythatha to its Board of …
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel …See details»
Redx & Jounce Announce Recommended Business Combination
The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points …See details»
Jounce Therapeutics Progresses INNATE Study of JTX-8064
Oct 7, 2021 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking Statements: Various statements in this release concerning Jounce’s future …See details»
Jounce Therapeutics Announces Pricing of $56.25 Million Public …
Mar 10, 2021 Investor and Media Contacts:Malin DeonJounce Therapeutics, Inc.+1-857-259-3843mdeon@jouncetx.com Mark YoreJounce Therapeutics, Inc.+1-857-200-1255 …See details»
Jounce Therapeutics Presents First Preclinical Data on Anti
Jun 22, 2020 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking StatementsVarious statements in this release concerning Jounce’s future …See details»
Jounce Therapeutics Reports Fourth Quarter and Full Year
Mar 2, 2022 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking Statements: Various statements in this release concerning Jounce’s future …See details»
Jounce Therapeutics | Cambridge MA - Facebook
Jounce Therapeutics, Cambridge, Massachusetts. 362 likes · 16 were here. Dedicated to Transforming the Treatment of CancerSee details»
Jounce Therapeutics Announces Results from Pre-Planned Data
Mar 16, 2023 Pimivalimab is a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. For more information, please visit www.jouncetx.com. Cautionary Note …See details»
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical …
Dec 8, 2022 - INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary …See details»